Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003759 · ClinicalTrials.gov registry record · Phase 2
AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer
A Phase 2 study of Bladder Cancer, sponsored by Anthra Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Study location
NCT00003759: Completed Phase 2 study of Bladder Cancer, sponsored by Anthra Pharmaceuticals.
NCT00003759 is a Phase 2 study of Bladder Cancer that has completed, run by Anthra Pharmaceuticals. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003759, a Phase 2 study of Bladder Cancer, has completed, sponsored by Anthra Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as BCG use different ways to stimulate the immune system and stop cancer cells from growing. It is not yet known whether AD 32 is more effective with or without BCG after surgery for superficial bladder cancer. PURPOSE: Randomized phase II trial to compare the effectiveness of AD 32 with or without BCG after surgery in treating patients who have newly diagnosed or recurrent superficial bladder cancer.
Conditions Studied
Interventions
- PROCEDURE conventional surgery
- DRUG valrubicin
- BIOLOGICAL BCG vaccine
Study Locations (1)
Texas
- University of Texas - MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-11 |
| Est. Completion | 2002-11 |
| Phase | Phase 2 |
What the finished NCT00003759 record still lists
NCT00003759 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Bladder Cancer appearing as the primary indexed condition, and to 3 interventions - of which conventional surgery is the first listed.
NCT00003759 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00003759 about?
NCT00003759 is a clinical study titled "AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as BCG use different ways to stimulate the immune system and stop cancer cells from growing. It is not yet known whether AD 32 is more effective with or w...
What is the current status of trial NCT00003759?
This trial is currently completed. It is a Phase 2 study. The study started on 1998-11. Estimated completion is 2002-11.
What conditions does trial NCT00003759 study?
This clinical trial studies the following conditions: Bladder Cancer.
What interventions are being tested in trial NCT00003759?
The interventions under investigation include: conventional surgery (PROCEDURE), valrubicin (DRUG), BCG vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003759?
This trial is sponsored by Anthra Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003759 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Telehealth Intervention for Ostomy Self-Management
RECRUITING · Phase 2
-
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
RECRUITING · Phase 2
-
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
RECRUITING · Phase 2
-
Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)
RECRUITING · Phase 2
-
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
RECRUITING · Phase 2
-
Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia